Ginkgo Bioworks Holdings Inc

For the period ended Jun 30, 2024. Filed Aug 8, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 8, 2024

DNA$12.01-2.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

	Three Months Ended June 30, 2024
	Common Stock
	Shares	Amount	AdditionalPaid-InCapital	Accumulated Deficit	AccumulatedOtherComprehensiveLoss	TotalStockholders’Equity
Balance as of March 31, 2024	2,033,624	$202	$6,445,058	$(5,456,439)	$(1,551)	$987,270
Issuance of common stock upon exercise or vesting of equity awards	21,472	2	12	—	—	14
Settlement of contingent consideration	1,972	—	2,570	—	—	2,570
Issuance of common stock for asset acquisitions	18,949	2	20,923	—	—	20,925
Issuance of common stock in exchange for services	2,720	—	2,500	—	—	2,500
Stock-based compensation expense	—	—	37,146	—	—	37,146
Foreign currency translation	—	—	—	—	(172)	(172)
Net loss	—	—	—	(217,181)	—	(217,181)
Balance as of June 30, 2024	2,078,737	$206	$6,508,209	$(5,673,620)	$(1,723)	$833,072
	Six Months Ended June 30, 2024
	Common Stock
	Shares	Amount	AdditionalPaid-InCapital	Accumulated Deficit	AccumulatedOtherComprehensiveLoss	TotalStockholders’Equity
Balance as of December 31, 2023	2,001,315	$199	$6,385,997	$(5,290,528)	$1,484	$1,097,152
Issuance of common stock upon exercise or vesting of equity awards	39,662	4	539	—	—	543
Settlement of contingent consideration	2,958	—	4,447	—	—	4,447
Issuance of common stock for asset acquisitions	32,082	3	36,798	—	—	36,801
Issuance of common stock in exchange for services	2,720	—	2,500	—	—	2,500
Stock-based compensation expense	—	—	77,928	—	—	77,928
Foreign currency translation	—	—	—	—	(3,207)	(3,207)
Net loss	—	—	—	(383,092)	—	(383,092)
Balance as of June 30, 2024	2,078,737	$206	$6,508,209	$(5,673,620)	$(1,723)	$833,072

Condensed Consolidated Statements of Stockholders’ Equity

	Three Months Ended June 30, 2023
	Common Stock
	Shares	Amount	AdditionalPaid-InCapital	Accumulated Deficit	AccumulatedOtherComprehensiveLoss	TotalStockholders’Equity
Balance as of March 31, 2023	1,933,880	$194	$6,211,634	$(4,602,628)	$(1,614)	$1,607,586
Issuance of common stock upon exercise or vesting of equity awards	15,995	2	470	—	—	472
Tax withholdings related to net share settlement of equity awards	(14)	—	(23)	—	—	(23)
Issuance of common stock for asset acquisitions	2,820	—	3,581	—	—	3,581
Issuance of common stock in exchange for services	2,023	—	2,500	—	—	2,500
Stock-based compensation expense and other	—	—	62,470	—	—	62,470
Foreign currency translation	—	—	—	—	314	314
Net loss	—	—	—	(173,315)	—	(173,315)
Balance as of June 30, 2023	1,954,704	$196	$6,280,632	$(4,775,943)	$(1,300)	$1,503,585
	Six Months Ended June 30, 2023
	Common Stock
	Shares	Amount	AdditionalPaid-InCapital	Accumulated Deficit	AccumulatedOtherComprehensiveLoss	TotalStockholders’Equity
Balance as of December 31, 2022	1,891,976	$190	$6,136,378	$(4,397,659)	$(2,632)	$1,736,277
Issuance of common stock upon exercise or vesting of equity awards	57,899	6	478	—	—	484
Tax withholdings related to net share settlement of equity awards	(14)	—	(23)	—	—	(23)
Settlement of contingent consideration - restricted stock	—	—	2,262	—	—	2,262
Issuance of common stock for asset acquisitions	2,820	—	3,581	—	—	3,581
Issuance of common stock in exchange for services	2,023	—	2,500	—	—	2,500
Stock-based compensation expense and other	—	—	135,456	—	—	135,456
Foreign currency translation	—	—	—	—	1,332	1,332
Net loss	—	—	—	(378,284)	—	(378,284)
Balance as of June 30, 2023	1,954,704	$196	$6,280,632	$(4,775,943)	$(1,300)	$1,503,585

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.